Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Int J Oncol
    July 2021
  1. KIM CJ, Terado T, Tambe Y, Mukaisho KI, et al
    Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/betacatenin/Ncadherin axis.
    Int J Oncol. 2021;59.
    >> Share

  2. PIAO XM, Hwang B, Jeong P, Byun YJ, et al
    Collagen type VIalpha1 and 2 repress the proliferation, migration and invasion of bladder cancer cells.
    Int J Oncol. 2021;59.
    >> Share

    December 2020
  3. BIAN J, Li B, Zeng X, Hu H, et al
    [Corrigendum] Mutation of TGFbeta receptor II facilitates human bladder cancer progression through altered TGFbeta1 signaling pathway.
    Int J Oncol. 2020 Dec 14. doi: 10.3892/ijo.2020.5161.
    >> Share

    September 2020
  4. LIU Z, Yang Y, Yang Z, Xia S, et al
    Novel circRNA_0071196/miRNA19b3p/CIT axis is associated with proliferation and migration of bladder cancer.
    Int J Oncol. 2020;57:767-779.
    >> Share

    March 2020
  5. PATEL R, Islam SA, Bommareddy RR, Smalley T, et al
    Simultaneous inhibition of atypical protein kinaseC and mTOR impedes bladder cancer cell progression.
    Int J Oncol. 2020 Mar 20. doi: 10.3892/ijo.2020.5021.
    >> Share

    February 2020
  6. ZHANG HH, Huang ZX, Zhong SQ, Fei KL, et al
    miR21 inhibits autophagy and promotes malignant development in the bladder cancer T24 cell line.
    Int J Oncol. 2020 Feb 13. doi: 10.3892/ijo.2020.4984.
    >> Share

    December 2019
  7. LIN F, Yin HB, Li XY, Zhu GM, et al
    Bladder cancer cellsecreted exosomal miR21 activates the PI3K/AKT pathway in macrophages to promote cancer progression.
    Int J Oncol. 2019 Dec 3. doi: 10.3892/ijo.2019.4933.
    >> Share

    November 2019
  8. XU M, Gu M, Zhou J, Da J, et al
    Interaction of YAP1 and mTOR promotes bladder cancer progression.
    Int J Oncol. 2019 Nov 25. doi: 10.3892/ijo.2019.4922.
    >> Share

    June 2019
  9. MORAN JD, Kim HH, Li Z, Moreno CS, et al
    SOX4 regulates invasion of bladder cancer cells via repression of WNT5a.
    Int J Oncol. 2019 Jun 26. doi: 10.3892/ijo.2019.4832.
    >> Share

  10. HORI S, Miyake M, Onishi S, Morizawa Y, et al
    Evaluation of pro and antitumor effects induced by three colonystimulating factors, GCSF, GMCSF and MCSF, in bladder cancer cells: Is GCSF a friend of bladder cancer cells?
    Int J Oncol. 2019;54:2237-2249.
    >> Share

    March 2019
  11. LIN JF, Tsai TF, Lin YC, Chen HE, et al
    Benzyl isothiocyanate suppresses IGF1R, FGFR3 and mTOR expression by upregulation of miR-99a-5p in human bladder cancer cells.
    Int J Oncol. 2019 Mar 26. doi: 10.3892/ijo.2019.4763.
    >> Share

  12. SUGITA S, Yoshino H, Yonemori M, Miyamoto K, et al
    Tumorsuppressive microRNA223 targets WDR62 directly in bladder cancer.
    Int J Oncol. 2019 Mar 22. doi: 10.3892/ijo.2019.4762.
    >> Share

    February 2019
  13. HUANG Z, Zhang M, Chen G, Wang W, et al
    Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4729.
    >> Share

    November 2018
  14. AZUMA H, Inamoto T, Takahara K, Ibuki N, et al
    Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
    Int J Oncol. 2018 Nov 2. doi: 10.3892/ijo.2018.4619.
    >> Share

    July 2018
  15. CHEN X, Xu Z, Zhu Z, Chen A, et al
    Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro.
    Int J Oncol. 2018 Jul 25. doi: 10.3892/ijo.2018.4501.
    >> Share

    June 2018
  16. SUGITA S, Enokida H, Yoshino H, Miyamoto K, et al
    HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4435.
    >> Share

    May 2018
  17. ZHANG L, Yang G, Zhang R, Dong L, et al
    Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells.
    Int J Oncol. 2018 May 30. doi: 10.3892/ijo.2018.4423.
    >> Share

    April 2018
  18. YANG X, Yin H, Zhang Y, Li X, et al
    Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1alpha activation.
    Int J Oncol. 2018 Apr 24. doi: 10.3892/ijo.2018.4376.
    >> Share

    March 2018
  19. LI C, Liu J, Zhang Q, Cui K, et al
    Upregulation of Ecadherin expression mediated by a novel dsRNA suppresses the growth and metastasis of bladder cancer cells by inhibiting beta-catenin/TCF target genes.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4346.
    >> Share

  20. LIU M, Chen Y, Huang B, Mao S, et al
    Tumor-suppressing effects of microRNA-612 in bladder cancer cells by targeting malic enzyme 1 expression.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4342.
    >> Share

  21. LIU J, Zhai R, Zhao J, Kong F, et al
    Programmed cell death 4 overexpression enhances sensitivity to cisplatin via the JNK/c-Jun signaling pathway in bladder cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4303.
    >> Share

    February 2018
  22. DU P, Ye L, Yang Y, Jiang WG, et al
    [Corrigendum] Candidate of metastasis 1 regulates in vitro growth and invasion of bladder cancer cells.
    Int J Oncol. 2018 Feb 16. doi: 10.3892/ijo.2018.4277.
    >> Share

    November 2017
  23. KIM CJ, Terado T, Tambe Y, Mukaisho KI, et al
    Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
    Int J Oncol. 2017 Nov 7. doi: 10.3892/ijo.2017.4194.
    >> Share

  24. LV XY, Ma L, Chen JF, Yu R, et al
    Knockdown of DUXAP10 inhibits proliferation and promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR signaling pathway.
    Int J Oncol. 2017 Nov 7. doi: 10.3892/ijo.2017.4195.
    >> Share

    August 2017
  25. SUN Y, Guan Z, Zhao W, Jiang Y, et al
    Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-kappaB signal-dependent and signal-independent manner.
    Int J Oncol. 2017 Aug 2. doi: 10.3892/ijo.2017.4089.
    >> Share

  26. YAMASHITA T, Higashi M, Momose S, Morozumi M, et al
    Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
    Int J Oncol. 2017;51:579-586.
    >> Share

    May 2017
  27. XIONG Y, Huang F, Li X, Chen Z, et al
    CCL21/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK/ERK1/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4003.
    >> Share

  28. CHEN M, Lv JM, Ye JQ, Cui XG, et al
    Disruption of serine/threonine protein phosphatase 5 inhibits tumorigenesis of urinary bladder cancer cells.
    Int J Oncol. 2017 May 16. doi: 10.3892/ijo.2017.3997.
    >> Share

  29. KIM WT, Seo SP, Byun YJ, Kang HW, et al
    Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis.
    Int J Oncol. 2017 May 11. doi: 10.3892/ijo.2017.3993.
    >> Share

    April 2017
  30. FENG C, Sun P, Hu J, Feng H, et al
    miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression.
    Int J Oncol. 2017 Apr 20. doi: 10.3892/ijo.2017.3969.
    >> Share

  31. WANG CY, Xu ZB, Wang JP, Jiao Y, et al
    Rb deficiency accelerates progression of carcinoma of the urinary bladder in vivo and in vitro through inhibiting autophagy and apoptosis.
    Int J Oncol. 2017;50:1221-1232.
    >> Share

  32. LIU Z, Liu J, Zhao L, Geng H, et al
    Curcumin reverses benzidine-induced epithelial-mesenchymal transition via suppression of ERK5/AP-1 in SV-40 immortalized human urothelial cells.
    Int J Oncol. 2017;50:1321-1329.
    >> Share

    March 2017
  33. HUSSAIN SA, Palmer DH, Syn WK, Sacco JJ, et al
    Gene expression profiling in bladder cancer identifies potential therapeutic targets.
    Int J Oncol. 2017 Mar 2. doi: 10.3892/ijo.2017.3893.
    >> Share

  34. HUSSAIN SA, Ansari J, Huddart R, Power DG, et al
    VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in t
    Int J Oncol. 2017;50:768-772.
    >> Share

    December 2016
  35. WANG JP, Jiao Y, Wang CY, Xu ZB, et al
    Rb knockdown accelerates bladder cancer progression through E2F3 activation.
    Int J Oncol. 2016 Dec 6. doi: 10.3892/ijo.2016.3791.
    >> Share

  36. CHEN L, Wang G, Luo Y, Wang Y, et al
    Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells.
    Int J Oncol. 2016 Dec 5. doi: 10.3892/ijo.2016.3788.
    >> Share

    November 2016
  37. KAMEYAMA K, Horie K, Mizutani K, Kato T, et al
    Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
    Int J Oncol. 2016 Nov 24. doi: 10.3892/ijo.2016.3781.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016